Johnson & Johnson (JNJ) Price & Analysis

Compare

149 Followers

JNJ Stock Chart & Stats

€199.06

-€0.18(-0.13%)

At close: Jan 09 4:00 PM EST

€199.06

-€0.18(-0.13%)

Day’s Range― - ―

52-Week Range€128.16 - €203.15

Previous CloseN/A

Volume223.00

Average Volume (3M)3.15K

Market Cap

€479.24B

Enterprise Value€600.47B

Total Cash (Recent Filing)€18.56B

Total Debt (Recent Filing)€45.80B

Price to Earnings (P/E)20.4

Beta0.19

Next Earnings

Apr 14, 2026

EPS Estimate

2.28

Next Dividend Ex-DateN/A

Dividend Yield2.54%

Share Statistics

EPS (TTM)2.09

Shares Outstanding2,409,295,200

10 Day Avg. Volume4,242

30 Day Avg. Volume3,154

Financial Highlights & Ratios

PEG Ratio-0.42

Price to Book (P/B)4.83

Price to Sales (P/S)3.88

P/FCF Ratio17.39

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€206.15

Price Target Upside3.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering13

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Margin Improvement And GuidanceManagement's plan to improve margins through identified profit-and-loss levers and royalty arrangement changes supports a stronger earnings outlook and has led analysts to raise estimates.

Portfolio StrategyStrategic portfolio actions like separating the orthopaedics business are intended to sharpen focus on core growth areas and redeploy capital toward high-growth pharmaceuticals and MedTech initiatives.

Product PipelineA broad biopharma pipeline with several late-stage and newly launched therapies such as Tremfya, Tecvayli and Darzalex provides a clear path to revenue growth and potential earnings beats if uptake and reimbursement progress.

Bears Say

Safety Profile ConcernsHigher rates of serious infections observed early with Tecvayli plus Darzalex prior to enhanced prophylaxis highlight safety risks that could slow adoption and complicate reimbursement discussions.

Talc Litigation RiskOngoing talc litigation remains an unresolved legal overhang that could result in material costs and weigh on investor sentiment if liabilities increase.

Valuation HeadwindsCurrent premium valuation limits the potential for further multiple expansion, which could constrain total return if operational growth falls short of expectations.

Johnson & Johnson News

TrumpRx website using technology from GoodRx, STAT says

President Trump is planning to announce the launch of his TrumpRx website, which uses technology from health care...

15h ago

AZN

BMY

Johnson & Johnson price target raised to $255 from $240 at RBC Capital

RBC Capital raised the firm’s price target on Johnson & Johnson to $255 from $240 and keeps an...

3d ago

JNJ

3 Dividend ETFs Paying 8%+ Passive Income

Dividend ETFs are popular with income-focused investors, but some stand out more than others. Using TipRanks’ High Dividend...

4d ago

ADI

JNJ

Johnson & Johnson price target raised to $227 from $221 at BofA

BofA raised the firm’s price target on Johnson & Johnson to $227 from $221 and keeps a Neutral...

7d ago

JNJ

Johnson & Johnson (JNJ) CEO Dumps $22M in Stock Post Q4 Results. Should Investors Worry?

Johnson & Johnson ($JNJ) CEO Joaquin Duato has sold a major block of company stock just days after...

8d ago

JNJ

PayPal downgraded, UPS upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

9d ago

Johnson & Johnson upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Johnson & Johnson to Overweight from Equal Weight with a price target of $262, up...

9d ago

JNJ

J&J confirms FDA approves quadruplet regimen for multiple myeloma

Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration approved Darzalex Faspro in combination with...

10d ago

JNJ

FDA approves Darzalex Faspro combo for newly diagnosed multiple myeloma

The Food and Drug Administration announced it has approved daratumumab and hyaluronidase-fihj, or Darzalex Faspro from Janssen Biotech,...

10d ago

JNJ

Johnson & Johnson call volume above normal and directionally bullish

Bullish option flow detected in Johnson & Johnson (JNJ) with 37,901 calls trading, 3x expected, and implied vol...

10d ago

JNJ

Top 3 Stocks to Watch Right Now, According to AI Analyst, 1/23/2026

The TipRanks AI Analyst tool scans analyst ratings, price targets, and market trends to highlight stocks with strong...

13d ago

JNJ

NEM

Johnson & Johnson price target raised to $240 from $227 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $240 from $227 and...

14d ago

JNJ

Johnson & Johnson price target raised to $265 from $230 at Scotiabank

Scotiabank raised the firm’s price target on Johnson & Johnson to $265 from $230 and keeps an Outperform...

15d ago

JNJ

Alphabet, Intel, Micron, J&J, Adobe Insider Moves

Insiders have been trading these 5 stocks: (($GOOG)), (($INTC)), (($MU)), (($JNJ)) and (($ADBE)). Here is a breakdown of...

6d ago

JNJ

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was €128.16 and its highest was €203.15 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is €479.24B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Apr 14, 2026 which is in 67 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Jan 21, 2026. The company reported €2.087 earnings per share for the quarter, missing the consensus estimate of €2.089 by -€0.003.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of €1.124 which represents an annual dividend yield of 2.54%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.28.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,409,295,200 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of €2.087 in its last earnings report, missing expectations of €2.089. Following the earnings report the stock price went down -1.197%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in DE:JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Neutral

Company Description

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights a dominant message of accelerating, portfolio-driven growth: robust revenue and adjusted EPS growth, strong free cash flow, numerous approvals and late-stage programs, and notable commercial momentum across oncology, immunology, neuroscience, and MedTech. Management provided constructive 2026 guidance, reiterated long-term ambition (double-digit growth by the end of the decade), and outlined capital deployment and the orthopedics separation. Offsetting risks include material STELARA biosimilar erosion (a substantial multi-hundred-basis-point headwind), elevated litigation and one-time charges, tariff pressures, competitive dynamics in select MedTech areas, and modest share-count dilution. On balance, the positives — broad-based commercial strength, pipeline and approval milestones, robust cash generation, and clear guidance — materially outweigh the near-term headwinds.View all DE:JNJ earnings summaries

JNJ Sales Breakdown

64.13% Innovative Medicine

35.87% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

€206.15

▲(3.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"130":"€130","225":"€225","153.75":"€153.8","177.5":"€177.5","201.25":"€201.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":224.81270495,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€224.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":206.14900869,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€206.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":184.09191311,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€184.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[130,153.75,177.5,201.25,225],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,194.02,196.38866961153846,198.75733922307694,201.1260088346154,203.49467844615387,205.86334805769232,208.23201766923077,210.60068728076925,212.9693568923077,215.33802650384615,217.70669611538463,220.07536572692308,222.44403533846156,{"y":224.81270495,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,194.02,194.95300066846156,195.88600133692307,196.81900200538462,197.75200267384616,198.68500334230768,199.61800401076923,200.55100467923077,201.48400534769232,202.41700601615383,203.35000668461538,204.28300735307693,205.21600802153844,{"y":206.14900869,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,194.02,193.25630100846155,192.4926020169231,191.72890302538462,190.96520403384616,190.2015050423077,189.43780605076924,188.67410705923078,187.91040806769232,187.14670907615385,186.3830100846154,185.61931109307693,184.85561210153847,{"y":184.09191311,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":141.997,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.678,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.017,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.468,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.873,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.511,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.652,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.185,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.227,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.288,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >